Full site coming soon
A new class of selective oncology therapeutics.
PharmaMatrix is a Canadian company based in Edmonton, exploring new treatments for cancers developed through computational chemistry by the Allard Chair in Research Oncology at University of Alberta, by its first Chair, Dr. Jack Tuszynski.
Data from the ongoing PMH-001 Phase I clinical trial in oncology is presented in a 2026 ASCO General Meeting Abstract, and additional information is available from the National Clinical Trials website. Follow the links below or use the Guide above.
ASCO 2026 · Abstract
PMH-001: A first-in-human Phase I study of the novel microtubule disruptor CCI-001 in patients with advanced cancer
ASCO Annual Meeting
ClinicalTrials.gov · NCT04823897
Phase I open-label dose-escalation study of CCI-001 as monotherapy and in combination with standard chemotherapy
Recurrent and/or metastatic solid tumours
Contact the team
Fill out the form below and we'll route your inquiry to the right person.